About SKB BIO Company

Sichuan Kelun Botai Biopharmaceutical Co., Ltd. (hereinafter referred to as "Kelun Botai" or the "Company") is a biopharmaceutical company focused on the research, development, manufacturing, and commercialization of innovative drugs. Since its establishment in 2016, it has remained committed to addressing unmet medical needs in China and around the world. Leveraging integrated drug-development capabilities and a robust management framework that encompasses all key business functions, Kelun Botai is dedicated to internally developing differentiated therapeutic approaches to help elevate current standards of healthcare. As one of the pioneers and leading developers of antibody–drug conjugates (ADCs), Kelun Botai has accumulated over a decade of experience in ADC development and is among the first batch of Chinese biopharmaceutical companies—and one of the few globally—to have established an integrated ADC R&D platform called OptiDC. The Company adopts a systematic, indication‑oriented approach to tackle prevalent or hard-to-treat cancers worldwide, as well as other diseases and conditions with large patient populations and significant unmet medical needs. Over the years, it has built end-to-end capabilities covering all major stages of drug development, including R&D, manufacturing, quality control, and commercialization, enabling it to strategically advance a pipeline of 33 differentiated, clinically valuable assets, 14 of which are in clinical stages. Supported by three proprietary technology platforms developed in-house, Kelun Botai has acquired specialized expertise in areas such as ADCs, large molecules—including monoclonal antibodies (mAbs) and bispecific antibodies (bsAbs)—and small‑molecule therapeutics, all of which have been validated by numerous clinical‑stage candidates. The Company has assembled a robust pipeline characterized by diversity across drug modalities, mechanisms of action, and indications, while also capable of generating synergistic effects. Decades of experience, industry relationships, and an extensive network held by its controlling shareholder, Kelun Pharmaceutical, have created favorable conditions for Kelun Botai to expand its commercial infrastructure and market channels. At the same time, the clinical value of Kelun Botai's pipeline and its drug-development capabilities have earned recognition from global strategic partners. To date, the Company has entered into nine external licensing agreements, including three development‑and‑license agreements with Merck Sharp & Dohme LLC (together with its affiliates, "Merck & Co.") for up to nine ADC assets targeting cancer treatment, with total upfront and milestone payments reaching as high as US$11.8 billion. These strategic collaborations not only underscore the Company's R&D and business‑development prowess but also serve as critical drivers of sustained innovation, global influence, and long-term growth. Looking ahead, Kelun Botai will strive to accelerate the commercialization of its pipeline and further enhance its integrated drug-development capabilities, continuing to lead the R&D and clinical activities of its candidate drugs. At the same time, the Company is committed to optimizing its R&D platforms and developing new technologies to support the discovery and advancement of innovative medicines. Additionally, Kelun Botai plans to expand its cGMP‑compliant manufacturing and quality‑control facilities and strengthen its internal commercialization functions, thereby supporting the launch of future pipeline assets and realizing its vision of becoming a globally leading biopharmaceutical company.